PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
-5.66%
Revenue decline while Medical - Pharmaceuticals median is 0.18%. Seth Klarman would investigate if market share loss is temporary.
-5.98%
Cost reduction while Medical - Pharmaceuticals median is 0.17%. Seth Klarman would investigate competitive advantage potential.
-4.38%
Gross profit decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
1.36%
Margin change of 1.36% versus flat Medical - Pharmaceuticals margins. Walter Schloss would verify quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
9.84%
Other expenses change of 9.84% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify efficiency.
1.36%
Operating expenses growth below 50% of Medical - Pharmaceuticals median of 4.04%. Joel Greenblatt would investigate efficiency.
-4.80%
Total costs reduction while Medical - Pharmaceuticals median is 3.25%. Seth Klarman would investigate advantages.
-5.00%
Interest expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
10.09%
D&A growth exceeding 1.5x Medical - Pharmaceuticals median of 1.13%. Jim Chanos would check for overinvestment.
22.67%
EBITDA change of 22.67% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
30.03%
Margin change of 30.03% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
-23.77%
Operating income decline while Medical - Pharmaceuticals median is -0.86%. Seth Klarman would investigate causes.
-19.20%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
296.84%
Other expenses growth exceeding 1.5x Medical - Pharmaceuticals median of 11.80%. Jim Chanos would check for issues.
-15.30%
Pre-tax income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-10.21%
Pre-tax margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-14.52%
Tax expense reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
-15.66%
Net income decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-10.60%
Net margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.66%
EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
-15.66%
Diluted EPS decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.